Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06303349
Other study ID # CHUBX 2023/45
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 7, 2024
Est. completion date June 2025

Study information

Verified date May 2024
Source University Hospital, Bordeaux
Contact Grégoire CANE, Dr
Phone 0557821019
Email gregoire.cane@chu-bordeaux.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective is to create a dynamic clinical prediction model that includes routinely measured care and biological biomarkers to predict cerebral vasospasm within 14 days of bleeding in patients treated in the neurosurgical intensive care unit for subarachnoid hemorrhage. Patients admitted to intensive care will be followed for up to 14 days (D14 time horizon of interest), or until discharge from intensive care if earlier. Blood samples will be taken from D1 to D10 to isolate the blood biomarkers of interest for each patient. The measurement of biomarkers and cerebral vasospasm will be blinded to each other.


Description:

Subarachnoid hemorrhage (SAH) is the rupture of a cerebral aneurysm, resulting in bleeding into the subarachnoid space. This condition has significant morbidity and mortality. The patient's functional outcome is primarily determined by the severity of cerebral ischemic lesions that develop during the first few weeks after the acute phase. The main focus of resuscitation management in patients are the 'delayed ischemic lesions'. These lesions are caused by various phenomena, with vasospasm being the most common mechanism. The caliber of cerebral arteries will shrink, reducing the blood flow delivered to the parenchyma, leading to a deficit of energy metabolites in neurons and causing their death. This complication typically occurs within a well-defined time frame, ranging from 3 to 21 days after bleeding, and peaking around the seventh day. The objective of this study is to create a novel predictive method for symptomatic vasospasm. This method will incorporate routine clinical and radiological biomarkers, as well as innovative biological assays. The aim is to enable earlier diagnosis and even pre-emptive treatment of this pathology. Several studies have examined the predictive potential of various blood biomarkers for neurological prognosis and the incidence of delayed brain damage in patients. These studies have demonstrated strong associations between them. For instance, one study found that patients with the most severe vasospasm had a significantly higher peak in cerebrospinal fluid of several biomarkers associated with neurodegeneration, such as Neuron Specific Enolase (NSE). Additionally, the plasma concentration-time curves demonstrated simultaneous elevations during periods of vasospasm. However, no study has examined the practical clinical use of these biomarkers during hospitalization to predict the occurrence of vasospasm on a daily basis or at specific times of interest. This is particularly important as the pathophysiological time sequence appears to be common to all patients. A single study has attempted to establish a predictive algorithm for delayed cerebral lesions, achieving a certain degree of effectiveness (over 90% correct predictions and sensitivity of around 93%), by combining a single biomarker assay and clinical parameters. However, this study only focuses on ischemic lesions at 6 weeks and cannot be used to guide therapy during initial management. Within the framework of a predictive statistical model, the investigators wish to study the possibility of combining routine clinical and radiological parameters with iterative assays of a panel of biomarkers covering several pathophysiological pathways (which would be easily assayable in the plasma of all patients) to predict on a daily basis (or at certain times of clinical interest) the risk of occurrence of cerebral vasospasm, with a view to being able to trigger diagnostic (or even therapeutic) procedures during initial management to prevent the ischemic cascade. To this end, the investigators have chosen 3 assays as a priority, targeting three previously described pathophysiological pathways. For neuroinflammation : - Interleukin-6 (IL-6) For cerebral cellular damage: - Neuron Specific Enolase (NSE) - The β-subunit of the S100 protein (S100 β) To enable this prediction, the investigators propose to use an innovative statistical method in the health sciences. Repeated biomarker assays can be integrated into complex event prediction models: the joint modeling of a longitudinal data model, for estimating individual biomarker trajectories over time, and a survival model, for estimating event risk with the current value or slope of the biomarker, enables precise event prediction. These models enable either static prediction (at a given time horizon) or dynamic prediction (with re-estimation of risk during follow-up). They also allow the concomitant integration of several biomarkers. Lastly, a model estimated on the study population could be transposed to other populations, thus making it possible to obtain risk models for this event. The aim of this research is to develop tools for daily clinical prediction of the onset of symptomatic vasospasm, using routine clinical and radiological parameters as well as innovative biological assays, with a view to triggering earlier diagnostic and even therapeutic responses than with the usual screening methods, which are severely limited and not always usable.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date June 2025
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subarachnoid hemorrhage (of aneurysmal or non-aneurysmal etiology) less than 4 days prior to admission to neuro-resuscitation, diagnosed on clinical presentation and confirmed by brain imaging. - Free, informed and written consent signed by the patient (or, failing this, his or her representative). - Patient entitled to or affiliated with social security Exclusion Criteria: - Significant vasospasm on admission to the department, diagnosed on initial imaging - Patient whose short-term survival (48 hours) appears compromised - Contraindication to perfusion CT scan - Pregnant or breast-feeding women - Patient under legal protection (persons deprived of liberty or under guardianship)

Study Design


Intervention

Other:
Samples collection
from D1 to D10, 1 SSTII (Serum separator tubes II) dry tube of 6 mL blood and 1 EDTA (Ethylenediamine tetraacetic acid) tube of 6 mL blood are collected. 1 SSTII dry tube of 6 mL cerebral spinal fluid will be collected distally in external ventricular drain, after eliminating the dead volume of the collection burette, for patients with it.

Locations

Country Name City State
France CHU de Bordeaux Bordeaux

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Bordeaux Bordeaux University

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of cerebral vasospasm Occurrence of cerebral vasospasm within 14 days of ICU (Intensive Care Unit) admission. Day 14 after inclusion
Secondary Biomarkers measurements Daily Serum measurements of the following markers from D1 to D10:
IL-6
NSE
S100 ß
Day 10 after inclusion
Secondary WFNS (World Federation of Neurologic Surgeons) score Initial WFNS score : From grade I (13% of bad evolution at 6 months) to grade V (68% of bad evolution à 6 months) up to Day 10 after inclusion
Secondary Glasgow score Hourly Glasgow score (scale from 3 :deep coma to 15 : fully conscious) up to Day 10 after inclusion
Secondary Medical Research Council (MRC) score Presence and intensity (MRC score) of motor deficit. scale from 0 : no movement is observed to 5 : full range of motion up to Day 10 after inclusion
Secondary PtiO2 (oxygen pressure in the cerebral tissue) Hourly PtiO2 data. up to Day 10 after inclusion
Secondary Transcranial Doppler Daily transcranial Doppler data from D1 to D10; up to Day 10 after inclusion
Secondary Modified Fisher score Modified Fisher score from initial imaging. Scale from 0(no subarachnoid hemorrhage / no intraventricular hemorrhage / incidence of symptomatic vasospasm: 0%) to 4 (thick subarachnoid hemorrhage / intraventricular hemorrhagepresent /the incidence of symptomatic vasospasm: 40%) up to Day 10 after inclusion
Secondary Non-significant angiographic vasospasm Presence of non-significant angiographic vasospasm on initial diagnostic/therapeutic arteriography or on follow-up imaging from D1 to D10. up to Day 10 after inclusion
Secondary Non-significant perfusion anomaly Presence of a non-significant perfusion anomaly on follow-up imaging from D1 to D10. up to Day 10 after inclusion
Secondary Glasgow Outcome Scale -Extended (GOS-E) GOS-E at ICU discharge. 8 levels (1 to 8) are in the scale: Minimum Score = 1 : Dead Maximum Score = 8 : Upper Good Recovery up to Day 14 after inclusion
Secondary Cerebral ischemic lesions Presence of delayed cerebral ischemic lesions on last imaging before discharge. up to Day 14 after inclusion
Secondary Occurrence of symptomatic vasospasm Occurrence of symptomatic vasospasm in non-severe SAH during ICU stay. up to Day 14 after inclusion
See also
  Status Clinical Trial Phase
Completed NCT02275949 - Acupuncture for Cerebral Vasospasm After Subarachnoid Hemorrhage N/A
Completed NCT02389634 - Identification of Novel Molecular Markers for Vasospasm
Completed NCT00962546 - Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage N/A
Not yet recruiting NCT04512859 - Stellate Ganglion Block in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage N/A
Completed NCT01024972 - Safety Study of Dantrolene in Subarachnoid Hemorrhage Phase 1/Phase 2
Completed NCT00692744 - Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH) N/A
Completed NCT04208477 - "The Effect of Stellate Ganglion Block in Severe Brain Injury" N/A
Recruiting NCT02129413 - Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm N/A
Terminated NCT00487461 - Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage N/A
Terminated NCT00582868 - Use of Brain Oxygen Tension Level and Cleaved-tau Protein to Detect Vasospasm After SAH N/A
Withdrawn NCT01878136 - Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage Phase 1/Phase 2
Withdrawn NCT01091870 - Sildenafil for Prevention of Cerebral Vasospasm Phase 2
Completed NCT03214705 - Role of CT Perfusion in Predicting Poor Outcome After Subarachnoid Hemorrhage
Recruiting NCT05150002 - Cervical Spinal Cord Stimulation in Patients With Cerebral Vasospasm After Subarachnoid Haemorrhage: VasoStim Study N/A
Completed NCT01187420 - Bilateral Bispectral Index (BIS) Study N/A
Enrolling by invitation NCT05230134 - Cervical Sympathetic Block in Patients With Cerebral Vasospasm N/A
Withdrawn NCT02426827 - Cervical Spinal Cord Stimulation in Cerebral Vasospasm N/A
Withdrawn NCT00871065 - Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm Phase 2
Recruiting NCT04691271 - Stellate Ganglion Block and Cerebral Vasospasm N/A
Recruiting NCT02432157 - Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage: Phase 1/Phase 2